BPC-157 / TB-500 Blend
A research peptide blend combining BPC-157 (Body Protection Compound) and TB-500 (Thymosin Beta-4 fragment), two tissue-repair peptides with complementary mechanisms involving angiogenesis, cell migration, and growth hormone receptor modulation. Preclinical studies suggest synergistic benefits in wound healing through overlapping yet distinct regenerative pathways.
BPC-157 and TB-500 (Thymosin Beta-4) are peptides commonly studied for their potential in promoting tissue repair and healing. BPC-157, a stable gastric pentadecapeptide derived from a protective protein in the stomach lining, accelerates healing by promoting angiogenesis and regulating growth factors, while TB-500 facilitates cellular migration to injury sites and reduces inflammation.
Overview
The potential synergy between BPC-157 and TB-500 arises from their overlapping yet distinct pathways in tissue repair. While BPC-157 excels at improving blood flow and reducing inflammation, TB-500 focuses on facilitating cellular migration to the injury site and supporting the repair process at the cellular level. Together, they may accelerate healing by addressing multiple aspects of tissue recovery, particularly in sports injuries or chronic conditions where regeneration is compromised. Early animal studies suggest this combination may lead to faster recovery times and improved structural integrity of repaired tissues.
Mechanism of Action
Cell Migration
Successful wound healing depends on fibroblasts, which regulate extracellular matrix production, as well as cells of the immune system. For these cells to function, they must migrate to the location of injury — a process heavily dependent on the protein actin. Both BPC-157 and TB-500 play important roles in actin regulation.
BPC-157 works at the gene level to increase actin production (Chang et al., 2010). TB-500, an actin-binding protein, helps sequester actin in areas where it is most useful for building filaments that allow cell movement (Philp et al., 2004). Together, BPC-157 and TB-500 work synergistically to increase the quantity and function of actin, thereby enhancing the rate at which fibroblasts and immune cells migrate to areas of injury.
Growth Hormone Receptor Modulation
Both TB-500 and BPC-157 interact with growth hormone in the healing process. BPC-157 increases the expression of growth hormone receptors on fibroblasts, boosting cell longevity and their ability to promote soft tissue regeneration (Chang et al., 2014). With TB-500 on board, the additional growth hormone receptors are utilized effectively because fibroblasts maintain adequate actin stores to make use of their extended lifespans. Combining TB-500, BPC-157, collagen, and a growth hormone secretagogue represents a potential avenue for enhanced wound healing rates.
Reconstitution Calculator
BPC-157 / TB-500 Blend
BPC-157 and TB-500 (Thymosin Beta-4) are peptides commonly studied for their pot
Set up a clean workspace with all supplies ready.
7x / week for weeks
Research
Tendon and Ligament Repair
Tendon healing is particularly challenging due to poor vascularity and slow cell turnover. BPC-157 promotes tendon outgrowth and fibroblast survival through FAK/paxillin signaling and has shown superior efficacy to bFGF, EGF, and VGF in tendon healing models. TB-500 contributes satellite cell activation, enhanced cell migration to the injury site, and anti-inflammatory support. The combination addresses the central challenge of tendon repair: getting enough cells and blood supply to a tissue with inherently limited regenerative capacity.
Chang et al. (2014) showed that BPC-157 enhances growth hormone receptor expression on tendon fibroblasts, increasing their responsiveness to growth signals. When combined with TB-500's actin-mediated enhancement of fibroblast motility, the result is fibroblasts that arrive faster at the injury site and respond more robustly to growth factor signaling once there.
Wound Healing Synergy
BPC-157 accelerates wound closure through dose-dependent stimulation of fibroblast proliferation, migration, and angiogenesis in alkali-burn models. TB-500 accelerates dermal wound healing in aged mice through enhanced collagen deposition and re-epithelialization. The combined application addresses both the vascular deficit (BPC-157 builds blood supply to the wound bed) and the cellular deficit (TB-500 mobilizes keratinocytes, fibroblasts, and endothelial cells to the wound). Philp et al. demonstrated that TB4 promotes wound healing through multiple parallel mechanisms including cell migration, collagen deposition, and angiogenesis — mechanisms that are amplified when vascular supply is simultaneously enhanced by BPC-157.
Cardiac and Vascular Applications
TB-500 has demonstrated remarkable cardioprotective properties. Bock-Marquette et al. (2004) showed that TB4 reduces infarct size through Akt activation, and Smart et al. (2007) demonstrated epicardial progenitor cell activation for cardiac regeneration. BPC-157 promotes collateral blood vessel formation in ischemic tissues and can bypass major venous occlusions in rat models. The combination pairs cardiomyocyte survival signaling (TB-500) with vascular remodeling (BPC-157), addressing both the cellular and vascular components of cardiac repair.
Tendon Healing and Outgrowth
BPC-157 has been shown to promote tendon healing through tendon outgrowth, cell survival, and cell migration in preclinical models. The peptide enhanced fibroblast proliferation and collagen organization in tendon explant cultures (Chang et al., 2010).
Thymosin Beta-4 in Tissue Repair
TB-500 promotes angiogenesis, wound healing, and tissue regeneration through its role as an actin-sequestering protein. Research demonstrates its capacity to stimulate endothelial cell migration and differentiation, contributing to new blood vessel formation at injury sites (Philp et al., 2004).
Gastrointestinal Healing
BPC-157 has a natural affinity for the GI tract as a derivative of gastric juice protein. It counteracts NSAID-induced, alcohol-induced, and ischemia-reperfusion GI lesions through VEGFR2-mediated angiogenesis and NO system modulation. TB-500's anti-inflammatory properties and cell migration enhancement provide complementary support. For GI applications, BPC-157 is the primary agent (given its oral bioavailability and gastric acid stability), with TB-500 providing systemic anti-inflammatory and tissue remodeling support. Kim and Jung (2015) demonstrated TB4's anti-fibrotic properties in liver tissue, suggesting the combination may also prevent excessive scarring in GI healing.
Fibrosis and Inflammatory Modulation
Thymosin Beta-4 has been investigated for its potential role in liver fibrosis, with findings suggesting it may modulate fibrotic processes through regulation of inflammatory pathways. These anti-fibrotic properties may extend to other tissue types when combined with BPC-157 (Kim & Jung, 2015).
Safety Profile
Both BPC-157 and TB-500 have demonstrated favorable safety profiles in preclinical studies, with no significant toxicity reported at standard research doses in animal models. BPC-157 has shown a wide therapeutic window in rodent studies with no observed lethal dose. TB-500 has been used in veterinary medicine (as Thymosin Beta-4) with limited adverse effects reported. However, human clinical safety data for the blend is lacking, and the long-term effects of combined administration have not been established.
Pharmacokinetic Profile
BPC-157 / TB-500 Blend — Pharmacokinetic Curve
Subcutaneous injectionOngoing & Future Research
- Head-to-head comparison studies of individual peptides vs. the combination are needed to quantify synergistic vs. additive effects.
- Investigation of optimal dosing ratios and timing protocols for the combination.
- Exploration of the combination for chronic conditions (osteoarthritis, chronic tendinopathy) requiring sustained tissue remodeling.
- Human clinical trial data for the combination remains the critical gap in the evidence base.
Quick Start
- Route
- Subcutaneous injection
Research Protocols
subcutaneous Injection
- Routes: BPC-157 subcutaneous or oral; TB-500 subcutaneous.
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| TB-500 dosing | 6 mg, 10-20 mg | Per protocol | — |
oral
For GI applications, BPC-157 is the primary agent (given its oral bioavailability and gastric acid stability), with TB-500 providing systemic anti-inflammatory and tissue remodeling support. Oral dosing at 10 µg/kg in drinking water also effective (PMID: 30598581).
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| BPC-157 dosing | 10 µg | Per protocol | —(Route: Oral) |
What to Expect
What to Expect
Effects begin within hours of administration based on half-life of BPC-157: ~4 hours; TB-500: ~6–8 hours
Due to short half-life (BPC-157: ~4 hours; TB-500: ~6–8 hours), effects are expected per-dose; consistent daily administration maintains therapeutic...
Regular administration schedule required; effects are dose-dependent and do not persist between doses
Quality Indicators
What to look for
- Well-established safety profile
- Multiple peer-reviewed studies available
Frequently Asked Questions
References (4)
- [3][Chang CH et al. (2014). Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules (2014)
- [4][Philp D et al. (2004). Thymosin beta4 promotes angiogenesis, wound healing, and hair follicle development. Mech Ageing Dev (2004)
- [1][Chang CH et al. (2010). The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (2010)
- [2]
Botulinum Toxin
Botulinum toxin is a potent neurotoxin produced by Clostridium botulinum that blocks acetylcholine release at neuromuscular junctions through SNARE protein cleavage. It is widely used therapeutically for dystonia, chronic migraine, hyperhidrosis, and cosmetically as Botox for dynamic wrinkle reduction.
BPC-157
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from human gastric juice that promotes wound healing, angiogenesis, and tissue repair through VEGFR2-mediated signaling. It demonstrates cytoprotective effects across gastrointestinal, musculoskeletal, cardiovascular, and neurological systems in preclinical models.